In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate.
This study examined the application of previously characterized microparticles composed of hyaluronan (HA) and chitosan hydroglutamate (CH) as well as novel microparticles consisting of both polymers (HA/CH) to improve the nasal delivery of a model drug. The rabbit bioavailabilities of gentamicin incorporated in HA, CH, and HA/CH microparticles were increased 23-, 31-, and 42-fold, respectively, compared with the control intranasal solution of gentamicin, indicating that all test microparticles were retained for longer periods on the nasal mucosa of the rabbits as supported by previous in vitro dissolution as well as frog palate mucoadhesion studies, thereby improving drug absorption. The higher bioavailabilities of CH-based formulations (CH and HA/CH) suggest the penetration-enhancing effects of CH may also be partially responsible for the improvement. A model was developed, based on a glass impinger device, to deliver dry powder formulations reproducibly onto the surface of cultured cell monolayers. In vitro permeability and fluorescence microscopy studies on the tight junctions of the 16HBE14o- cell lines further confirmed the ability of CH-based formulations to enhance penetration. Furthermore, the in vitro absorption profile from cell culture studies was consistent with those determined from in vivo studies. The complementary effect from the mucoadhesive nature of HA coupled with the penetration-enhancing effects of CH makes the novel HA/CH formulation a promising nasal delivery system.
Lim
S T
ST
MedPharm Ltd, Department of Pharmacy, King's College London, London SE1 9NN.
Forbes
B
B
Martin
G P
GP
Brown
M B
MB
D000281:Administration, Intranasal; D000336:Aerosols; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects; D002686:Chitin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology*; D048271:Chitosan; D004337:Drug Carriers; D004847:Epithelial Cells / Q000378:metabolism; D005839:Gentamicins / Q000008:administration & dosage / Q000378:metabolism; D018698:Glutamic Acid / Q000737:chemistry; D006820:Hyaluronic Acid / Q000494:pharmacology*; D008863:Microspheres; D011817:Rabbits; D019108:Tight Junctions / Q000187:drug effects / Q000378:metabolism
D000336:Aerosols; D004337:Drug Carriers; D005839:Gentamicins; D002686:Chitin; D018698:Glutamic Acid; D006820:Hyaluronic Acid; D048271:Chitosan